Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class ...

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Windtree Therapeutics (WINT) announced that an istaroxime presentation featuring the positive Phase 2b SEISMiC study was given on February 11, ...

Auron Therapeutics has raised a $27 million Series ... driving the programs forward,” Yen said. Don't miss out on Boston-area life science news. Subscribe to the Morning Edition or Afternoon ...

PureTech Founded Entity Seaport Therapeutics Announces Publication of New Research Demonstrating Increased Lymphatic Transport with Glyph Platform ...

Health industry leaders and advocates come together for The Boston Globe's Rare Disease Summit, featuring powerful conversations with the rare disease community on Tuesday, February 25, 2025 from 10 a ...

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the ...

MONDAY, Feb. 10, 2025 (HealthDay News) -- Surgeons at Massachusetts General Hospital have successfully performed the fourth ...

Best-in-class highly selective HDAC6 inhibitor pioneer for disease-modifying treatment of neuromuscular, neurodegenerative and cardiometabolic diseases poised to enter the clinic ...